Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial.

Abstract

BACKGROUND:

Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic myelopathy characterized by motor dysfunction of the lower extremities and urinary disturbance. Immunomodulatory treatments are the main strategy for HAM/TSP, but several issues are associated with long-term treatment. We conducted a clinical trial with prosultiamine (which has apoptotic activity against HTLV-I-infected cells) as a novel therapy in HAM/TSP patients.

METHODS:

We enrolled 24 HAM/TSP patients in this open-label clinical trial. Prosultiamine (300 mg, orally) was administered once daily for 12 weeks. We monitored changes in the motor function of the lower extremities and urinary function as well as copy numbers of the HTLV-I provirus in peripheral blood mononuclear cells (PBMCs).

RESULTS:

Improvement in the motor function of the lower extremities based on a reduction in spasticity (for example, decrease in time required for walking and descending a flight of stairs) was observed. In an urodynamic study (UDS), bladder capacity and detrusor pressure and then maximum flow rate increased significantly. Detrusor overactivity and detrusor-sphincter dyssynergia improved in 68.8% and 45.5% of patients observed at pretreatment, respectively. Improvement in UDS corresponded with improvements in the score of nocturia-quality of life questionnaire. HTLV-I proviral copy numbers in PBMCs decreased significantly (approximately 15.4%) compared with pretreatment levels.

CONCLUSIONS:

These data suggest that prosultiamine can safely improve motor dysfunction of the lower extremities and urinary disturbance as well as reduce HTLV-I provirus levels in peripheral blood. It therefore has potential as a new therapeutic tool for HAM/TSP patients.

TRIAL REGISTRATION:

University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) number, UMIN000005969. Please see related commentary: http://www.biomedcentral.com/1741-7015/11/183.

• Authors: Tatsufumi Nakamura, Tomohiro Matsuo, Taku Fukuda, Shinji Yamato, Kentaro Yamaguchi, Ikuo Kinoshita, Toshio Matsuzaki, Yoshihiro Nishiura, Kunihiko Nagasato, Tomoko Narita-Masuda, Hideki Nakamura, Katsuya Satoh, Hitoshi Sasaki, Hideki Sakai, Atsushi Kawakami
• Journal: BMC medicine (BMC Med) Vol. 11 Pg. 182 (Aug 15 2013) ISSN: 1741-7015 [Electronic] England
• PMID: 23945290 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• prosultiamine
• Thiamine

Topics

• Adolescent
• Adult
• Child
• Child, Preschool
• Female
• HTLV-I Infections (drug therapy, pathology)
• Humans
• Leg (physiology)
• Leukocytes, Mononuclear (virology)
• Male
• Middle Aged
• Motor Activity
• Proviruses (isolation & purification)
• Thiamine (analogs & derivatives, therapeutic use)
• Treatment Outcome
• Urination (physiology)
• Viral Load
• Young Adult